Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Clin Immunol ; 38(8): 917-926, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-30470982

RESUMO

The results of hematopoietic stem cell transplant (HSCT) for primary immunodeficiency diseases (PID) have been improving over time. Unfortunately, developing countries do not experience the same results. This first report of Brazilian experience of HSCT for PID describes the development and results in the field. We included data from transplants in 221 patients, performed at 11 centers which participated in the Brazilian collaborative group, from July 1990 to December 2015. The majority of transplants were concentrated in one center (n = 123). The median age at HSCT was 22 months, and the most common diseases were severe combined immunodeficiency (SCID) (n = 67) and Wiskott-Aldrich syndrome (WAS) (n = 67). Only 15 patients received unconditioned transplants. Cumulative incidence of GVHD grades II to IV was 23%, and GVHD grades III to IV was 10%. The 5-year overall survival was 71.6%. WAS patients had better survival compared to other diseases. Most deaths (n = 53) occurred in the first year after transplantation mainly due to infection (55%) and GVHD (13%). Although transplant for PID patients in Brazil has evolved since its beginning, we still face some challenges like delayed diagnosis and referral, severe infections before transplant, a limited number of transplant centers with expertise, and resources for more advanced techniques. Measures like newborn screening for SCID may hasten the diagnosis and ameliorate patients' conditions at the moment of transplant.


Assuntos
Doença Enxerto-Hospedeiro/epidemiologia , Transplante de Células-Tronco Hematopoéticas , Síndromes de Imunodeficiência/terapia , Doenças Raras/terapia , Brasil/epidemiologia , Diagnóstico Tardio , Países em Desenvolvimento , Feminino , Doença Enxerto-Hospedeiro/mortalidade , Humanos , Síndromes de Imunodeficiência/epidemiologia , Síndromes de Imunodeficiência/mortalidade , Lactente , Recém-Nascido , Masculino , Triagem Neonatal , Doenças Raras/epidemiologia , Doenças Raras/mortalidade , Análise de Sobrevida
2.
J Cataract Refract Surg ; 29(6): 1222-5, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12842694

RESUMO

We report a case of corneal ectasia detected 32 months after laser in situ keratomileusis (LASIK) for correction of -4.25 diopters (D) of myopia associated with -2.00 D of regular but slight asymmetric astigmatism. The patient retained stable visual acuity for 15 months postoperatively. The preoperative corneal thickness was 540 microm, and the postablation untouched stroma was assumed to be 290 microm. Although a rare complication of LASIK, corneal ectasia can occur, and there is no consensus regarding how much stroma should be left intact to avoid it. Until we have a better understanding of corneal strength, we think surface photorefractive keratectomy or laser-assisted subepithelial keratectomy ablations should be considered instead of LASIK in borderline cases.


Assuntos
Astigmatismo/cirurgia , Córnea/patologia , Doenças da Córnea/diagnóstico , Doenças da Córnea/etiologia , Ceratomileuse Assistida por Excimer Laser In Situ/efeitos adversos , Miopia/cirurgia , Pré-Escolar , Topografia da Córnea , Dilatação Patológica/diagnóstico , Dilatação Patológica/etiologia , Humanos , Masculino , Acuidade Visual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA